Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 26, 2026

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

Modeling combined radiopharmaceutical therapy: a linear optimization framework.

Ian M Besse1, Mark T Madsen, David L Bushnell

  • 1Applied Mathematical and Computational Sciences, University of Iowa, Iowa City, IA, USA. ibesse@math.uiowa.edu

Technology in Cancer Research & Treatment
|January 27, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preliminary Evaluation of 225Ac/177Lu-DOTATATE PRRT in Progressive Meningiomas: Efficacy, Dosimetry, and Imaging Insights.

Clinical nuclear medicine·2026
Same author

Self-citation in nursing research: Patterns, outliers, and empirical thresholds.

Nursing outlook·2026
Same author

FAP-Targeted Theranostics in Advanced Sarcoma: A Pilot Study of ⁶⁸Ga-FAPI-46 Imaging and ¹⁷⁷Lu-FAPI-2286 Therapy.

Clinical nuclear medicine·2026
Same author

Epidemiology of Thyroid Cancer in Jordan Over Two Decades: 2000-2019.

JCO global oncology·2026
Same author

Multidisciplinary management of meningiomas in the era of precision oncology.

Nature reviews. Clinical oncology·2026
Same author

PET Molecular Imaging and Theranostics in Lung Diseases: Making Precision Medicine a Reality.

Chest·2026
Same journal

Research on Predicting the Efficacy of Immunotherapy for Non-small Cell Lung Cancer Based on CT Radiomics and Peripheral Blood Inflammatory Markers.

Technology in cancer research & treatment·2026
Same journal

Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study.

Technology in cancer research & treatment·2026
Same journal

Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy.

Technology in cancer research & treatment·2026
Same journal

EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies.

Technology in cancer research & treatment·2026
Same journal

Developing and Validating a Risk Model for Severe Bone Marrow Suppression in Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy: A Retrospective Cohort Study.

Technology in cancer research & treatment·2026
Same journal

A Novel Adjustable Tandem and Ring Applicator for Improved Dosimetry in Cervical Cancer HDR Brachytherapy.

Technology in cancer research & treatment·2026
See all related articles

This study mathematically proves combination radiopharmaceutical therapy can be superior to single-agent treatments. The findings offer methods for optimizing radiation doses for patients receiving these innovative cancer therapies.

Area of Science:

  • Medical Physics
  • Radiopharmaceutical Therapy
  • Mathematical Modeling

Background:

  • Radiopharmaceutical therapy uses radioactive substances to treat diseases, primarily cancer.
  • Optimizing radiation dose delivery to tumors while sparing critical organs is a key challenge.
  • Previous models have explored the effects of radiopharmaceuticals, but combination therapies require further investigation.

Purpose of the Study:

  • To mathematically validate a model for combined radiopharmaceutical therapy.
  • To determine conditions under which dual-agent therapy outperforms single-agent therapy.
  • To develop methods for calculating optimal radioactivity dosages for combination treatments.

Main Methods:

  • Mathematical modeling of radiation dose distribution.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Jun 26, 2026

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

  • Analysis of a dual-agent radiopharmaceutical therapy model.
  • Derivation of patient-specific conditions for treatment optimization.
  • Generalization of the model for multiple agents and treatment factors.

    • Main Results:

    • The model proves that combination therapy is superior to single-agent therapy under specific patient conditions.
    • General methods are outlined for calculating optimal administered radioactivity for dual-agent therapies.
    • The model is extendable to include multiple radiopharmaceuticals and other treatment variables.

    Conclusions:

    • Mathematical modeling provides a framework for optimizing complex radiopharmaceutical therapies.
    • Combination radiopharmaceutical therapy offers potential advantages over single-agent approaches.
    • This work lays the foundation for personalized, multi-agent radiopharmaceutical treatment planning.